METHOD OF TREATING DISORDERS USING SELECTIVE NR2B SUBTYPE NMDA RECEPTOR ANTAGONIST Russian patent published in 2013 - IPC A61K31/505 A61P25/16 A61P25/28 

FIELD: medicine.

SUBSTANCE: group of inventions refers to medicine and aims at treating, preventing or relieving a disease or a condition which is to be treated, prevented or relieved by NMDA receptor inhibition. The method involves administering a total daily dose of approximately 2 to approximately 50 mg of a compound of formula

or a pharmaceutically acceptable salt thereof into the patient in need thereof. What is also declared is using the compound of formula (I) or a pharmaceutically acceptable salt thereof for treating, preventing or relieving the course of a cognitive disorders, a neurodegenerative disorder, pain, depression, attention deficient hyperactivity disorder or an addiction, and for treating, preventing or relieving the course of a disease or a disorder by inhibition of NMDA receptors containing an NR2B subunit wherein a total daily dose of the compound makes from approximately 2 to approximately 50 mg.

EFFECT: group of the inventions is high effective in treating, preventing or relieving the course of a disease or a disorder which is to be treated, prevented or relieved by NMDA receptor inhibition.

10 cl, 6 dwg, 3 ex